Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.69 |
| ▸ | CA2 | P00918 | 14/20 | 0.69 |
| ▸ | CA9 | Q16790 | 5/20 | 0.69 |
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144238 | 0.86 | CA1 (0.64) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL15325018 | 0.85 | CA1 (0.70) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL24138188 | 0.85 | KDM4E (0.64) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL27734101 | 0.85 | CA1 (0.71) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL17806453 | 0.85 | CA1 (0.71) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL6359413 | 0.84 | ALDH1A1 (0.78) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL10592850 | 0.84 | KDM4E (0.84) | ALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL27557893 | 0.83 | KDM4E (0.62) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL3783605 | 0.83 | KDM4E (0.62) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL20738432 | 0.83 | ALDH1A1 (0.77) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3736268-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-108299251-B | Preparation method of glimepiride impurity | 山东新华制药股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3082819-B1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-9783505-B2 | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2706057-A1 | Bis(imidazolyl)compounds and radionuclide complexes | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| CN-1250210-C | The use of sulfonylureas and sulphonyl thiourea derivative in preparation of anti diabetes drug | UNIV CHINA PHARMA (CN) | 2006-04-12 | — | — | CN | disclosed |
| CN-1218700-C | Usage of sulfonylureas derivant in the preparing process of blood vessel embolism disease treating medicine | UNIV CHINA PHARMA (CN) | 2005-09-14 | — | — | CN | disclosed |
| CN-1569006-A | Usage of sulfonylureas derivant in the preparing process of blood vessel embolism disease treating medicine | UNIV CHINA PHARMA (CN) | 2005-01-26 | — | — | CN | disclosed |
| CN-1557287-A | The use of sulfonylureas and sulphonyl thiourea derivative in preparation of anti diabetes drug | 中国药科大学 | 2004-12-29 | — | — | CN | disclosed |
| US-5516906-A | Process for the preparation of N-[2-[4-(aminosulfonyl) phenyl]ethyl]5-methylpyrazinecarboxamide | USV LIMITED (IN) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | CA1 4870/4885CA2 4606/4885CA9 3996/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | CA1 4238/4885CA2 4222/4885CA9 3587/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | CA1 4238/4885CA2 4222/4885CA9 3587/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA1 3353/4885CA2 3978/4885CA9 4566/4885 |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | CA1 3884/4885CA2 1821/4885CA9 3900/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | CA1 4870/4885CA2 4606/4885CA9 3996/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | CA1 4870/4885CA2 4606/4885CA9 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.